Results 11 to 20 of about 2,000 (177)

Emerging concepts in HIV pre-exposure prophylaxis: focus on twice-yearly lenacapavir [PDF]

Drugs in Context
The persistent global burden of HIV and the need for more flexible, durable prevention strategies have accelerated the development of long-acting pre-exposure prophylaxis (PrEP) options.
Sarah L Anderson
doaj   +3 more sources

Subtypes A1 and D, and recombinant HIV-1 natural polymorphisms associated with lenacapavir drug resistance in Uganda [PDF]

Journal of Antimicrobial Chemotherapy
Background Lenacapavir, a novel HIV-1 capsid inhibitor, shows promise for treating MDR HIV-1, as well as for pre-exposure prophylaxis (PrEP) in prevention of HIV infection.
Suzanne McCluskey, Daniel Omoding, Guinevere Q Lee   +2 more
exaly   +4 more sources

Lenacapavir for HIV Prevention in Africa: Opportunities, Barriers, and Policy Priorities [PDF]

Journal of the International Association of Providers of AIDS Care
Despite global progress in HIV prevention, Africa continues to carry a disproportionate share of the epidemic and its related inequalities. Daily oral pre-exposure prophylaxis (PrEP) has been limited by adherence and accessibility challenges. Lenacapavir,
Stanley Chinedu Eneh, Francisca Ogochukwu Onukansi, Chidera Gabriel Obi, Collins Chibueze Anokwuru, Ogechi Vinaprisca Ikhuoria, Moses Ifeatu Nwuzoh, Samson Adiaetok Udoewah, Moses Obinna John, Onyeka Chukwudalu Ekwebene, Udokang Ephraim Ikpongifono, Chioma Adaora Nwalieji, Louis Oguchukwu Ugwulor, Okoli Chukwudinma Chigozie, Temitope Olumuyiwa Ojo   +13 more
doaj   +3 more sources

Potential impact and cost-effectiveness of long-acting injectable lenacapavir plus cabotegravir as HIV treatment in Africa [PDF]

Nature Communications
Although viral suppression is attained for most adults living with diagnosed HIV in East, Central, Southern and West Africa (ECSWA), challenges remain with sustained adherence to daily oral pill taking for some in the population.
Andrew Phillips, Jennifer Smith, Loveleen Bansi-Matharu, Kenly Sikwese, Cissy Kityo, Charles Flexner, Marco Vitoria, Nathan Ford, Meg Doherty, Zack Panos, David Ripin, Matthew Hickey, Diane Havlir, Monica Gandhi, Michael Reid, Paul Revill   +15 more
doaj   +3 more sources

Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient

Case Reports in Infectious Diseases, 2023
We report a hemodialysis MDR HIV-infected patient switched to fostemsavir with lenacapavir plus lamivudine for more than a year. She maintained a suppressed viral replication and did not present any clinical or biological drug-related side effects.
Ferdinand Bigirimana, Sigi Van den Wijngaert, Christelle Fosso, Karolien Stoffels, Charlotte Martin, Evelyne Maillart, Philippe Clevenbergh   +6 more
doaj   +2 more sources

Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations

Viruses, 2022
Long-acting (LA) anti-HIV regimens show promise for increasing dosing intervals and consequently, improving the patients’ quality of life. The first FDA-approved LA therapy is Cabenuva, which comprises rilpivirine (a non-nucleoside reverse transcriptase ...
Maria E. Cilento, Yee Tsuey Ong, Philip R. Tedbury, Stefan G. Sarafianos   +3 more
doaj   +2 more sources

A French national observatory of people with HIV initiating lenacapavir-based treatment after regulatory approval [PDF]

Antimicrobial Agents and Chemotherapy
There is limited data on lenacapavir (LEN) use, the newest capsid inhibitor, in observational settings. We describe population characteristics and pharmaco-virological outcomes of people with HIV-1 (PWH) who initiated LEN-based treatment.
Charlotte Charpentier, Thomas Montrouge, Marc Wirden, Véronique Avettand-Fenoel, Camille Tumiotto, Pantxika Bellecave, Audrey Rodallec, Elisabeth Garnier, Djeneba Fofana, Sidonie Lambert-Niclot, Brigitte Montès, Marie-Laure Chaix, Caroline Charre, Pierre Gantner, Magali Bouvier-Alias, Enagnon Kazali Alidjinou, Pauline Coulon, Gilbert Mchantaf, Agnès Beby-Defaux, Elodie Alessandri-Gradt, Alice Moisan, Quentin Le Hingrat, Minh Lê, Constance Delaugerre, Anne-Geneviève Marcelin, Gilles Peytavin, Vincent Calvez, Diane Descamps   +27 more
doaj   +2 more sources

Lenacapavir: una revisión bibliográfica del fármaco que promete erradicar el VIH desde la profilaxis [PDF]

Ciencia & Salud
Describir las características clínicas, la eficacia y los retos de accesibilidad del lenacapavir, un inhibidor de la cápside viral del VIH con aplicaciones en tratamiento y profilaxis preexposición (PrEP).
Ivo Heyerdahl-Viau
doaj   +2 more sources

FDAs new approval: yeztugo (lenacapavir): a longer lasting avenue against HIV

Journal of the Pakistan Medical Association
Dear Editor, The human immunodeficiency virus is an RNA retrovirus transmitted through bodily fluids: blood, semen, pre-seminal fluid, rectal fluids, vaginal fluids, and breast milk.
Maryam Tanveer, Ahsan Kamal
doaj   +2 more sources

The primary mechanism for highly potent inhibition of HIV-1 maturation by lenacapavir.

PLoS Pathogens
Lenacapavir (LEN) is a highly potent, long-acting antiretroviral medication for treating people infected with muti-drug-resistant HIV-1 phenotypes. The inhibitor targets multifaceted functions of the viral capsid protein (CA) during HIV-1 replication ...
Szu-Wei Huang, Lorenzo Briganti, Arun S Annamalai, Juliet Greenwood, Nikoloz Shkriabai, Reed Haney, Michael L Armstrong, Michael F Wempe, Satya Prakash Singh, Ashwanth C Francis, Alan N Engelman, Mamuka Kvaratskhelia   +11 more
doaj   +2 more sources